Ronapreve Archives -

NICE has recommended that three COVID-19 therapies can continue to be used to treat patients – Pfizer’s Paxlovid,

NICE rejects five COVID drugs and backs three on price, efficacy data

https://pharmaphorum.com/news/nice-rejects-five-covid-drugs-and-backs-three-on-price-efficacy-data/

AstraZeneca’s AZD7442 has shown that it can prevent COVID-19 infection when given to healthy patients – the first

PROVENT trial puts AZ COVID antibody combo back on track

https://pharmaphorum.com/news/provent-trial-puts-az-covid-antibody-combo-back-on-track/

Phase 3 results with Roche’s amyloid-targeting Alzheimer’s drug gantenerumab may not be due until the second half of

Roche ‘talking to FDA’ as Alzheimer’s drug moves towards 2022 readout

https://pharmaphorum.com/news/roche-talking-to-fda-as-alzheimers-drug-moves-towards-2022-readout/

Ronapreve